PAVmed (PAVM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 May, 2026Executive summary
Annual meeting scheduled for June 24, 2026, to be held virtually, with record date set as April 27, 2026.
Three main proposals: election of two Class A directors, amendments to the Employee Stock Purchase Plan (ESPP), and ratification of the independent auditor.
Board recommends voting in favor of all proposals.
Proxy materials are primarily distributed online to reduce environmental impact and costs.
Voting matters and shareholder proposals
Election of Ronald M. Sparks and Timothy Baxter as Class A directors for three-year terms.
Amendments to ESPP: increase available shares by 200,000 (to 215,774) and raise annual evergreen limit to 500,000 shares.
Ratification of CBIZ CPAs as independent auditor for fiscal year ending December 31, 2026.
Board recommends voting FOR all proposals.
No appraisal or dissenters' rights for any proposal.
Board of directors and corporate governance
Board divided into three classes; majority are independent directors.
Board committees: audit, compensation, and nominating/corporate governance, all comprised of independent directors.
Lead independent director role held by Ronald M. Sparks; independent directors meet in executive session.
Board met five times in 2025; all directors attended at least 75% of meetings.
Board oversees risk management, with committees responsible for specific risk areas.
Latest events from PAVmed
- Virtual annual meeting to vote on director elections, ESPP amendments, and auditor ratification.PAVM
Proxy filing30 Apr 2026 - Registering 9.2M shares for resale after a $30M private placement; proceeds fund operations.PAVM
Registration filing21 Apr 2026 - Restructuring and recapitalization drove growth, improved financials, and expanded diagnostic access.PAVM
Q4 20252 Apr 2026 - Record test growth and revenue surge, but losses and funding risks persist.PAVM
Q2 202426 Mar 2026 - Q1 2025 net income reached $17.7M as Lucid and Veris advanced, but going concern risks persist.PAVM
Q1 202526 Mar 2026 - Stabilized finances, advanced diagnostics, and expanded digital health amid ongoing capital needs.PAVM
Q3 202526 Mar 2026 - Q2 2025 featured 2,756 EsoGuard tests, $1.2M revenue, and strengthened liquidity.PAVM
Q2 202526 Mar 2026 - Votes are sought on stock issuance, governance changes, and expanded equity incentives.PAVM
Proxy Filing24 Feb 2026 - Proxy seeks approval for stock issuance, charter amendment, and expanded equity plan.PAVM
Proxy Filing13 Feb 2026